Personalized Immuno-Oncology
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-030-62080-6_20
Reference85 articles.
1. Akiki M, Haddad FG, Kourie HR, et al. PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. Biomark Med. 2019;13:1539–41.
2. Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther. 2012;12:251–7.
3. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–40.
4. Bastien JP, Minguy A, Dave V, Roy DC. Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. Semin Immunol. 2019;42:101306.
5. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines. 2004;3:521–7.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunologic tumor microenvironment modulators for turning cold tumors hot;Cancer Communications;2024-03-29
2. Exploring the Potential of Azo Compounds in Leukemia Treatment: Synthesis and Characterization of New Derivatives with Dimedone and Meldrum's Acid End Groups;ChemistrySelect;2023-09-19
3. New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies;Life;2021-10-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3